Hederagenin attenuates renal senescence in diabetic kidney disease by inhibiting DNMT1-mediated Klotho DNA methylation

Abstract

Background Hederagenin is a naturally occurring pentacyclic triterpenoid found in several medicinal plants traditionally used for treating renal and metabolic disorders. Its ability to mitigate renal senescence in diabetic kidney disease (DKD) and the associated epigenetic mechanisms have not yet been fully elucidated. Methods db/db mice were used in vivo to model DKD-associated renal senescence, while palmitic acid-treated human renal proximal tubular epithelial cells (HK-2 cells) were used in vitro as a senescence model. Renal injury, senescence, DNA damage, and Klotho expression were evaluated using histological, biochemical, and molecular analyses. GEO datasets derived from human DKD samples and corresponding controls were analyzed to assess Klotho expression. Integrated target-binding and methylation analyses were performed to examine the interaction between hederagenin and DNA methyltransferase 1 (DNMT1), as well as the effects of hederagenin on Klotho promoter methylation and DNMT1 occupancy. Results Hederagenin reduced renal senescence, fibrosis, and DNA damage in vivo and in vitro, while restoring Klotho expression, which was decreased in patient datasets and experimental models. Mechanistically, hederagenin directly bound DNMT1, diminished DNMT1 recruitment to the Klotho promoter, and attenuated aberrant promoter hypermethylation, thereby reactivating Klotho. Conclusion Hederagenin mitigates renal senescence in DKD through a DNMT1-Klotho DNA methylation axis, supporting its ethnopharmacological potential for DKD management.

Keywords

Diabetic kidney disease / Hederagenin / DNA methylation / Senescence / Klotho

Funding

This work was supported by the National Natural Science Foundation of China (Nos. 82274510, 82474454, 82405070, 82360918), the Natural Science Foundation of Guangdong Province, China (No. 2024A1515012173), and the Jiangxi Provincial Administration of Traditional Chinese Medicine Science and Technology Plan (No. 2023B0597).

Declaration of competing interest

These authors have no conflict of interest to declare.

Data availability

Data will be available on request by sending E-mail to the corresponding authors.

References

[1] Tuttle KR, Agarwal R, Alpers CE, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022; 102(2):248-260. https://doi.org/10.1016/j.kint.2022.05.012.

[2] Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018; 71(6):884-895. https://doi.org/10.1053/j.ajkd.2017.10.026.

[3] Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380(24):2295-2306. https://doi.org/10.1056/NEJMoa1811744.

[4] Liu MN, Li XL, Gao YH, et al. Breaking the fibrotic code: nanotechnology-driven advances in renal fibrosis therapy. Biomaterials. 2026; 327:123738. https://doi.org/10.1016/j.biomaterials.2025.123738.

[5] Zhang HZ, Li Y, Liu Y. An updated review of the pharmacological effects and potential mechanisms of hederagenin and its derivatives. Front Pharmacol. 2024; 15:1374264. https://doi.org/10.3389/fphar.2024.1374264.

[6] Xie KH, Liu XH, Jia J, et al. Hederagenin ameliorates cisplatin-induced acute kidney injury via inhibiting long non-coding RNA A330074k22Rik/Axin2/β-catenin signalling pathway. Int Immunopharmacol. 2022; 112:109247. https://doi.org/10.1016/j.intimp.2022.109247.

[7] Jia J, Xu LH, Deng C, et al. Hederagenin ameliorates renal fibrosis in chronic kidney disease through blocking ISG15 regulated JAK/STAT signaling. Int Immunopharmacol. 2023; 118:110122. https://doi.org/10.1016/j.intimp.2023.110122.

[8] Yang W, He LJ. The protective effect of hederagenin on renal fibrosis by targeting muscarinic acetylcholine receptor. Bioengineered. 2022; 13(4):8689-8698. https://doi.org/10.1080/21655979.2022.2054596.

[9] Jia J, Tan RZ, Xu LH, et al. Hederagenin improves renal fibrosis in diabetic nephropathy by regulating Smad3/NOX4/SLC7A11 signaling-mediated tubular cell ferroptosis. Int Immunopharmacol. 2024; 135:112303. https://doi.org/10.1016/j.intimp.2024.112303.

[10] Yang GH, Yang W, Jiang HR, et al. Hederagenin inhibits high glucose-induced fibrosis in human renal cells by suppression of NLRP3 inflammasome activation through reducing cathepsin B expression. Chem Biol Drug Des. 2023; 102(6):1409-1420. https://doi.org/10.1111/cbdd.14332.

[11] Liu TL, Li XL, Chen YD, et al. Natural products in treating diabetic kidney disease: a visualized bibliometric analysis. Front Pharmacol. 2025; 16:1522074. https://doi.org/10.3389/fphar.2025.1522074.

[12] Schubeler D. Function and information content of DNA methylation. Nature. 2015; 517(7534):321-326. https://doi.org/10.1038/nature14192.

[13] Akhouri V, Majumder S, Gaikwad AB. Targeting DNA methylation in diabetic kidney disease: a new perspective. Life Sci. 2023; 335:122256. https://doi.org/10.1016/j.lfs.2023.122256.

[14] Gao Q, Chen F, Zhang LJ, et al. Inhibition of DNA methyltransferase aberrations reinstates antioxidant aging suppressors and ameliorates renal aging. Aging Cell. 2022; 21(1):e13526. https://doi.org/10.1111/acel.13526.

[15] Jiang W, Gan C, Zhou XD, et al. Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease. Cardiovasc Diabetol. 2023; 22(1):293. https://doi.org/10.1186/s12933-023-02025-.

[16] Kim SS, Song SH, Kim IJ, et al. Decreased plasma alpha-Klotho predict progression of nephropathy with type 2 diabetic patients. J Diabetes Complicat. 2016; 30(5):887-892. https://doi.org/10.1016/j.jdiacomp.2016.03.006.

[17] Lee EY, Kim SS, Lee JS, et al. Soluble α-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes. PLoS One. 2014; 9(8):e102984. https://doi.org/10.1371/journal.pone.0102984.

[18] Chen GH, Xu HL, Wu YT, et al. Myricetin suppresses the proliferation and migration of vascular smooth muscle cells and inhibits neointimal hyperplasia via suppressing TGFBR1 signaling pathways. Phytomedicine. 2021; 92:153719. https://doi.org/10.1016/j.phymed.2021.153719.

[19] Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16(1):6-21. https://doi.org/10.1101/gad.947102.

[20] Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005; 65(14):6305-6311. https://doi.org/10.1158/0008-5472.CAN-04-2957.

[21] Gros C, Fleury L, Nahoum V, et al. New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors. J Biol Chem. 2015; 290(10):6293-6302. https://doi.org/10.1074/jbc.M114.594671.

[22] Pan C, Wang XL, Fan ZC, et al. Polystyrene microplastics facilitate renal fibrosis through accelerating tubular epithelial cell senescence. Food Chem Toxicol. 2024; 191:114888. https://doi.org/10.1016/j.fct.2024.114888.

[23] Kim DY, Lee M, Kim EJ. Involvement of Klotho, TNF-α; and ADAMs in radiation-induced senescence of renal epithelial cells. Mol Med Rep. 2021; 23(1):22. doi: 10.3892/mmr.2020.11660

[24] Miao JH, Huang JW, Luo CW, et al. Klotho retards renal fibrosis through targeting mitochondrial dysfunction and cellular senescence in renal tubular cells. Physiol Rep. 2021; 9(2):e14696. https://doi.org/10.14814/phy2.14696.

[25] Typiak M, Piwkowska A. Antiinflammatory actions of Klotho: implications for therapy of diabetic nephropathy. Int J Mol Sci. 2021; 22(2):956. doi: 10.3390/ijms22020956

[26] Azuma M, Koyama D, Kikuchi J, et al. Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB J. 2012; 26(10):4264-4274. https://doi.org/10.1096/fj.12-21163.

[27] Yin SS, Zhang Q, Yang J, et al. TGFβ-incurred epigenetic aberrations of miRNA and DNA methyltransferase suppress Klotho and potentiate renal fibrosis. Biochim Biophys Acta Mol Cell Res. 2017; 1864(7):1207-1216. https://doi.org/10.1016/j.bbamcr.2017.03.002.

[28] Li YN, Chen F, Wei A, et al. Klotho recovery by genistein via promoter histone acetylation and DNA demethylation mitigates renal fibrosis in mice. J Mol Med (Berl). 2019; 97(4):541-552. https://doi.org/10.1007/s00109-019-01759-.

[29] Zhang Q, Liu L, Lin WJ, et al. Rhein reverses Klotho repression via promoter demethylation and protects against kidney and bone injuries in mice with chronic kidney disease. Kidney Int. 2017; 91(1):144-156. https://doi.org/10.1016/j.kint.2016.07.040.

[30] Yu DM, Zhang LE, Yu GQ, et al. Association of liver and kidney functions with Klotho gene methylation in a population environment exposed to cadmium in China. Int J Environ Health Res. 2020; 30(1):38-48. https://doi.org/10.1080/09603123.2019.1572106.

[31] Liu MN, Li XL, Zhang L, et al. Rhubarb in renal fibrosis: from traditional ethnopharmacology to mechanistic therapeutic development. Chin J Nat Med. 2026; 24(5):526-542. doi: 10.1016/S1875-5364(25)60947-2

[32] Sarwar MS, Cheng D, Peter RM, et al. Metabolic rewiring and epigenetic reprogramming in leptin receptor-deficient db/db diabetic nephropathy mice. Eur J Pharmacol. 2023; 953:175866. https://doi.org/10.1016/j.ejphar.2023.175866.

[33] Yu ZH, Xu ZY, Liang Y, et al. Vitamin C deficiency causes cell type-specific epigenetic reprogramming and acute tubular necrosis in a mouse model. J Am Soc Nephrol. 2022; 33(3):531-546. https://doi.org/10.1681/ASN.2021070881.

[34] Ouyang L, Su XY, Li WX, et al. ALKBH1-demethylated DNA N6-methyladenine modification triggers vascular calcification via osteogenic reprogramming in chronic kidney disease. J Clin Invest. 2021; 131(14):e146985. doi: 10.1172/JCI146985

[35] Seelan RS, Mukhopadhyay P, Pisano MM, et al. Effects of 5-aza-2'-deoxycytidine (decitabine) on gene expression. Drug Metab Rev. 2018; 50(2):193-207. https://doi.org/10.1080/03602532.2018.1437446.

[36] Kim DY, Cheong HT, Ra CS, et al. Effect of 5-azacytidine (5-aza) on UCP2 expression in human liver and colon cancer cells. Int J Med Sci. 2021; 18(10):2176-2186. https://doi.org/10.7150/ijms.56564.

[37] Bertoli RM, Chung YJ, Difilippantonio MJ, et al. The DNA methyltransferase inhibitor 5-aza-4'-thio-2'-deoxycytidine induces C > G transversions and acute lymphoid leukemia development. Cancer Res. 2024; 84(15):2518-2532. https://doi.org/10.1158/0008-5472.CAN-23-2785.

[38] Zhao X, Ruan ZY, Qin XL, et al. The role of 5-aza-2'-deoxycytidine on methylation status of Xist gene in different genders of buffalo (Bubalus bubalis) bone marrow mesenchymal stem cells. Cell Reprogram. 2019; 21(2):89-98. https://doi.org/10.1089/cell.2018.0040.

[39] Mohan KN. DNMT1: catalytic and non-catalytic roles in different biological processes. Epigenomics. 2022; 14(10):629-643. https://doi.org/10.2217/epi-2022-0035.

[40] Syed AA, Reza MI, Garg R, et al. Cissus quadrangularis extract attenuates diabetic nephropathy by altering SIRT1/DNMT1 axis. J Pharm Pharmacol. 2021; 73(11):1442-1450. https://doi.org/10.1093/jpp/rgab078.

[41] Zhang L, Zhang QM, Liu SX, et al. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney Int. 2017; 92(1):140-153. https://doi.org/10.1016/j.kint.2017.01.010.

[42] Jin L, Niu C, Ni YL. Correlation between peripheral blood α1-MG, DNMT1 expression, and the severity of diabetic nephropathy renal pathological damage. Medicine (Baltimore). 2023; 102(42):e35409. https://doi.org/10.1097/MD.0000000000035409.

[43] Chen GC, Chen HH, Ren SY, et al. Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease. Kidney Int. 2019; 96(2):409-420. https://doi.org/10.1016/j.kint.2019.02.020.

[44] Zeng S, Wu XY, Chen XY, et al.Hypermethylated in cancer 1 (HIC1) mediates high glucose induced ROS accumulation in renal tubular epithelial cells by epigenetically repressing SIRT1 transcription. Biochim Biophys Acta Gene Regul Mech. 2018; 1861(10):917-927. https://doi.org/10.1016/j.bbagrm.2018.08.002.

[45] Zhao Q, Wang B, Chen S. Application of hederagenin in preparing an antihyperlipidemic drug. China patent CN1385158A. Published December 18, 2002.

[46] Su F, Sui X, Xu J, et al. Hederagenin suppresses ovarian cancer via targeting mitochondrial fission through dynamin-related protein 1. European Journal of Pharmacology. 2024; 963:176188. https://doi.org/10.1016/j.ejphar.2023.176188.

[47] Xie ZS, Zhao JP, Wu LM, et al. Hederagenin improves Alzheimer’s disease through PPARα/TFEB-mediated autophagy. Phytomedicine. 2023; 112:154711. https://doi.org/10.1016/j.phymed.2023.154711.

[48] Zeng J, Huang T, Xue M, et al. Current knowledge and development of hederagenin as a promising medicinal agent: a comprehensive review. RSC Adv. 2018; 8(43):24188-24202. https://doi.org/10.1039/c8ra03666.